A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer

Inclusion Criteria: * Patients aged 18 years or over with histologically verified adenocarcinoma of colon or rectum. * Recurrent of metastatic disease not amenable to curative surgery and/or radiotherapy. * Life expectancy greater than 3 months. * Karnofsky Index Score greater than or equal to 50%. * Written informed consent obtained. Exclusion Criteria: * Neoplastic lesions other than colorectal cancer (except treated basal cell carcinoma of the skin or cancer of the uterine cervix, through Stage I. * Acute intercurrent illness. * Patient considered to be a medical risk because of non-malignant systemic disease or grossly abnormal laboratory results. * Patients who had received any other anticancer therapy within 3 months. * Factor liable to alter the serum gastrin concentration or affect intra-gastric acidity, for instance concomitant therapy with H2 receptor antagonist drugs, proton pump inhibitors, or previous gastric surgery. * Patients immunologically compromised including those on corticosteroid therapy. * Women of child-bearing age. * Positive immediate hypersensitivity reaction to skin testing with study medication. * Patients unable to complete the diary book * Haematogical Status Haemoglobin count less than 10g/dL White Blood Cell count less than 4.0 x 10\^9/L Platelet count less than 100 x 10\^9/L